Drug firm Strides Pharma Science Ltd. has got tentative approval from U.S. health regulator for Diclofenac Potassium Softgel Capsules, a drug used to relieve pain.
Strides Pharma Global Pte Ltd, Singapore, has received tentative approval for Diclofenac Potassium Softgel Capsules, 25 mg from the United States Food & Drug Administration, Strides Pharma Science said in a regulatory filing.
-
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
India Could Gain If AI Trade Unwinds, US Midterms May Hurt Markets: Ramesh Damani -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI -
"I Am A Material Man In A Material World': Quantum Advisors' Ajit Dayal On NDTV Profit Ignite
Strides Pharma Global Pte Ltd is a step-down wholly-owned subsidiary of Strides Pharma Science. The product is a generic version of Zipsor Capsules in the strength of 25 milligrams of Assertio Therapeutics, Inc.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Diclofenac Potassium Softgel capsule is a nonsteroidal anti-Inflammatory drug used to relieve pain and swelling. It is used to treat muscle aches, backaches, dental pain, menstrual cramps, and sports injuries.
Diclofenac Potassium Softgel capsules is part of Strides niche and small volume product portfolio with limited competition in the U.S. market.
According to research firm IQVIA MAT data, the U.S. market for Diclofenac Potassium Softgel capsules, 25 milligrams is approximately $30 million.
Strides can launch the product earliest by September 2022 based on terms of settlement. On receiving full approval, the product will be manufactured at the company's Oral dosage facility in Bengaluru and marketed by Strides Pharma Inc in the U.S. Market.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
